van den Heerik, Anne Sophie V M http://orcid.org/0000-0001-6403-0143
Horeweg, Nanda http://orcid.org/0000-0002-8581-4753
Nout, Remi A
Lutgens, Ludy C H W
van der Steen-Banasik, Elzbieta M
Westerveld, G Henrike
van den Berg, Hetty A
Slot, Annerie
Koppe, Friederike L A
Kommoss, Stefan
Mens, Jan Willem M
Nowee, Marlies E
Bijmolt, Stefan
Cibula, David
Stam, Tanja C
Jurgenliemk-Schulz, Ina M
Snyers, An
Hamann, Moritz
Zwanenburg, Aleida G
Coen, Veronique L M A
Vandecasteele, Katrien
Gillham, Charles
Chargari, Cyrus
Verhoeven-Adema, Karen W
Putter, Hein
van den Hout, Wilbert B
Wortman, Bastiaan G
Nijman, Hans W
Bosse, Tjalling
Creutzberg, Carien L
Clinical trials referenced in this document:
Documents that mention this clinical trial
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
https://doi.org/10.1136/ijgc-2020-001929
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Adjuvant chemotherapy and radiation for patients with high-risk stage I endometrial cancer treated with curative intent surgery: impact on recurrence and survival
https://doi.org/10.1136/ijgc-2021-003087
Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy
https://doi.org/10.1136/ijgc-2021-002380
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
The time is now to start molecular subtyping high-intermediate and high-risk endometrial cancers
https://doi.org/10.1136/ijgc-2022-003709
Funding for this research was provided by:
KWF Kankerbestrijding (UL2011-5336 and 12376)